<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01362673</url>
  </required_header>
  <id_info>
    <org_study_id>A9391012</org_study_id>
    <nct_id>NCT01362673</nct_id>
  </id_info>
  <brief_title>PK And Safety Study Of PF-04171327 In Healthy Japanese And Western Subjects In Fasting And Fed Conditions</brief_title>
  <official_title>A Phase 1, Randomized, Subject- And Investigator Blind, Sponsor Open, Placebo Controlled, Single- And Multiple-Dose Escalation Study Of PF-04171327 In Healthy Adult Japanese And Western Subjects In Fasting And Fed Conditions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This Phase 1 study is the first clinical trial in Japanese subjects. This study is designed
      to evaluate the single- and multiple-dose pharmacokinetics, safety and tolerability of
      PF-04171327 oral tablet in healthy adult Japanese and Western subjects in fasting and fed
      conditions.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2011</start_date>
  <completion_date type="Actual">August 2011</completion_date>
  <primary_completion_date type="Actual">August 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Plasma pharmacokinetic parameters for PF-00251802 : Cmax</measure>
    <time_frame>Day 1 to Day 4 in each period of Cohort A</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma pharmacokinetic parameters for PF-00251802 : Tmax</measure>
    <time_frame>Day 1 to Day 4 in each period of Cohort A</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma pharmacokinetic parameters for PF00251802 : AUC(0-last)</measure>
    <time_frame>Day 1 to Day 4 in each period of Cohort A</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma pharmacokinetic parameters for PF-00251802 : As data permit AUC(0-inf)</measure>
    <time_frame>Day 1 to Day 4 in each period of Cohort A</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma pharmacokinetic parameters for PF-00251802 : As data permit t1/2</measure>
    <time_frame>Day 1 to Day 4 in each period of Cohort A</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma pharmacokinetic parameters for N-oxide metabolite (PF-04015475): Cmax</measure>
    <time_frame>Day 1 to Day 4 in each period of Cohort A</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma pharmacokinetic parameters for N-oxide metabolite (PF-04015475): Tmax</measure>
    <time_frame>Day 1 to Day 4 in each period of Cohort A</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma pharmacokinetic parameters for N-oxide metabolite (PF-04015475): AUC(0-last)</measure>
    <time_frame>Day 1 to Day 4 in each period of Cohort A</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma pharmacokinetic parameters for N-oxide metabolite (PF-04015475): As data permit AUC(0-inf)</measure>
    <time_frame>Day 1 to Day 4 in each period of Cohort A</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma pharmacokinetic parameters for N-oxide metabolite (PF-04015475): As data permit t1/2</measure>
    <time_frame>Day 1 to Day 4 in each period of Cohort A</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma pharmacokinetic parameters for PF-00251802: Cmax for Day 1 and Day 12</measure>
    <time_frame>Day 1 to Day 15 in Cohort B</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma pharmacokinetic parameters for PF-00251802: Tmax for Day 1 and Day 12</measure>
    <time_frame>Day 1 to Day 15 in Cohort B</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma pharmacokinetic parameters for PF-00251802: AUCtau for Day 1 and Day 12</measure>
    <time_frame>Day 1 to Day 15 in Cohort B</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma pharmacokinetic parameters for PF-00251802: As data permit t1/2 for Day12</measure>
    <time_frame>Day 1 to Day 15 in Cohort B</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma pharmacokinetic parameters for PF-00251802: As data permit Rac (accumulation ratio = Day 12 AUCtau/Day 1 AUCtau) for Day12</measure>
    <time_frame>Day 1 to Day 15 in Cohort B</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma pharmacokinetic parameters for PF-00251802: Ctrough</measure>
    <time_frame>Day 1 to Day 15 in Cohort B</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma pharmacokinetic parameters for N-oxide metabolite (PF-04015475): Cmax for Day 1 and Day 12</measure>
    <time_frame>Day 1 to Day 15 in Cohort B</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma pharmacokinetic parameters for N-oxide metabolite (PF-04015475): Tmax for Day 1 and Day 12</measure>
    <time_frame>Day 1 to Day 15 in Cohort B</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma pharmacokinetic parameters for N-oxide metabolite (PF-04015475): AUCtau for Day 1 and Day 12</measure>
    <time_frame>Day 1 to Day 15 in Cohort B</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma pharmacokinetic parameters for N-oxide metabolite (PF-04015475): As data permit t1/2 for Day12</measure>
    <time_frame>Day 1 to Day 15 in Cohort B</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma pharmacokinetic parameters for N-oxide metabolite (PF-04015475): As data permit Rac (accumulation ratio = Day 12 AUCtau/Day 1 AUCtau) for Day12</measure>
    <time_frame>Day 1 to Day 15 in Cohort B</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma pharmacokinetic parameters for N-oxide metabolite (PF-04015475): Ctrough</measure>
    <time_frame>Day 1 to Day 15 in Cohort B</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Biomarkers for bone effects: Serum procollagen type 1 N-terminal propeptide (P1NP), serum C terminal telopeptide of type I collagen (CTX), serum osteocalcin and urine N terminal telopeptide of type I collagen (uNTX).</measure>
    <time_frame>Day 0 to Day 15 in Cohort B</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarkers for carbohydrate and metabolic: Plasma cortisol, serum glucose, plasma insulin and serum adiponectin.</measure>
    <time_frame>Day 0 to Day 15 in Cohort B</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">27</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Single dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Multiple dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-04171327</intervention_name>
    <description>Oral single 5 mg dose as one 5 mg tablet</description>
    <arm_group_label>Single dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-04171327</intervention_name>
    <description>Oral single 10 mg dose as one 10 mg tablet</description>
    <arm_group_label>Single dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-04171327</intervention_name>
    <description>Oral single 30 mg dose as three 10 mg tablets</description>
    <arm_group_label>Single dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Oral single dose as matching placebo</description>
    <arm_group_label>Single dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-04171327</intervention_name>
    <description>Oral multiple 20 mg doses as two 10 mg tablets for 12 days</description>
    <arm_group_label>Multiple dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Oral multiple doses as matching placebo for 12 days</description>
    <arm_group_label>Multiple dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male and/or female subjects of non childbearing potential between the ages of
             18 and 55 years.

          -  Body Mass Index (BMI) of 17.5 to 30.5 kg/m2; and a total body weight &gt;45 kg (99 lbs).

          -  Japanese subjects who have four Japanese grandparents born in Japan.

        Exclusion Criteria:

          -  Confirmed fasting glucose more than 100 mg/dL at Screening and Day 0 in both Cohort A
             and B.

          -  Corticosteroid use of more than 5 mg prednisone equivalent per day for more than 6
             weeks.

          -  Evidence or history of clinically significant hematological (including anemia), renal,
             endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric,
             neurologic, or allergic disease (including drug allergies, but excluding untreated,
             asymptomatic, seasonal allergies at the time of dosing).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Glendale</city>
        <state>California</state>
        <zip>91206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A9391012&amp;StudyName=PK%20And%20Safety%20Study%20Of%20PF-04171327%20In%20Healthy%20Japanese%20And%20Western%20Subjects%20In%20Fasting%20And%20Fed%20Conditions</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>October 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 17, 2011</study_first_submitted>
  <study_first_submitted_qc>May 26, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 30, 2011</study_first_posted>
  <last_update_submitted>October 5, 2011</last_update_submitted>
  <last_update_submitted_qc>October 5, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 7, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Phase 1</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>food effect</keyword>
  <keyword>Healthy Japanese</keyword>
  <keyword>rheumatoid arthritis</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

